Takeda Pharmaceutical Co Stock Current Liabilities
| TAK Stock | USD 13.38 0.02 0.15% |
Takeda Pharmaceutical Co fundamentals help investors to digest information that contributes to Takeda Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Takeda Stock. The fundamental analysis module provides a way to measure Takeda Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Takeda Pharmaceutical stock.
At this time, Takeda Pharmaceutical's Total Current Liabilities is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 6.2 T this year, although the value of Non Current Liabilities Other will most likely fall to about 383.9 B. Takeda | Current Liabilities |
Takeda Pharmaceutical Co Company Current Liabilities Analysis
Takeda Pharmaceutical's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Takeda Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Takeda Pharmaceutical is extremely important. It helps to project a fair market value of Takeda Stock properly, considering its historical fundamentals such as Current Liabilities. Since Takeda Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Takeda Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Takeda Pharmaceutical's interrelated accounts and indicators.
Click cells to compare fundamentals
Takeda Current Liabilities Historical Pattern
Today, most investors in Takeda Pharmaceutical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Takeda Pharmaceutical's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Takeda Pharmaceutical current liabilities as a starting point in their analysis.
Takeda Pharmaceutical Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Takeda Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Takeda Pharmaceutical Co has a Current Liabilities of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Takeda Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Takeda Pharmaceutical's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Takeda Pharmaceutical could also be used in its relative valuation, which is a method of valuing Takeda Pharmaceutical by comparing valuation metrics of similar companies.Takeda Pharmaceutical is currently under evaluation in current liabilities category among related companies.
Takeda Pharmaceutical Current Valuation Drivers
We derive many important indicators used in calculating different scores of Takeda Pharmaceutical from analyzing Takeda Pharmaceutical's financial statements. These drivers represent accounts that assess Takeda Pharmaceutical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Takeda Pharmaceutical's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.5T | 3.2T | 2.7T | 3.4T | 3.9T | 4.7T | |
| Enterprise Value | 7.0T | 6.8T | 6.2T | 7.3T | 6.5T | 3.8T |
Takeda Fundamentals
| Return On Equity | 0.0276 | ||||
| Return On Asset | 0.0261 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 4.94 T | ||||
| Shares Outstanding | 3.14 B | ||||
| Shares Owned By Institutions | 2.66 % | ||||
| Number Of Shares Shorted | 8.12 M | ||||
| Price To Earning | 27.57 X | ||||
| Price To Book | 0.95 X | ||||
| Price To Sales | 0.01 X | ||||
| Revenue | 4.03 T | ||||
| Gross Profit | 2.44 T | ||||
| EBITDA | 1.21 T | ||||
| Net Income | 317.04 B | ||||
| Cash And Equivalents | 533.53 B | ||||
| Cash Per Share | 208.91 X | ||||
| Total Debt | 4.38 T | ||||
| Debt To Equity | 0.81 % | ||||
| Current Ratio | 1.18 X | ||||
| Book Value Per Share | 4,297 X | ||||
| Cash Flow From Operations | 977.16 B | ||||
| Short Ratio | 5.26 X | ||||
| Earnings Per Share | 0.36 X | ||||
| Price To Earnings To Growth | 3.23 X | ||||
| Target Price | 18.37 | ||||
| Number Of Employees | 49.09 K | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 41.92 B | ||||
| Total Asset | 13.96 T | ||||
| Retained Earnings | 1.54 T | ||||
| Working Capital | (83.98 B) | ||||
| Annual Yield | 0.05 % | ||||
| Five Year Return | 4.54 % | ||||
| Net Asset | 13.96 T | ||||
| Last Dividend Paid | 184.0 |
About Takeda Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Takeda Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Takeda Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Takeda Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:Check out Takeda Pharmaceutical Piotroski F Score and Takeda Pharmaceutical Altman Z Score analysis. Note that the Takeda Pharmaceutical information on this page should be used as a complementary analysis to other Takeda Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Takeda Stock analysis
When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Takeda Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.12) | Dividend Share 184 | Earnings Share 0.36 | Revenue Per Share 1.3 K | Quarterly Revenue Growth 0.013 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.